Takeda, bracing for Vyvanse patent loss, makes strides on debt goal and pivots its focus to launches

Ever since Takeda closed its Shire takeover, the company has prioritized cutting its debt. After selling off some dispensable assets, the Japanese pharma is moving closer to its goal and is increasingly shifting its focus to growing revenue with new drugs.

After paying off 560.8 billion Japanese yen ($4.32 billion) worth of debt during the company’s 2021 fiscal year, Takeda has lowered its debt to earnings ratio to 2.8x as of the end of March versus 3.2x the same time last year.